Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis - Pipeline Review, H2 2016, provides an overview of the Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline landscape.
Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axial Spondyloarthritis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Unknown stages are 2, 5, 2 and 1 respectively.Axial Spondyloarthritis.
Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Eli Lilly and Company
Johnson & Johnson
Novartis AG
Panacea Biotec Ltd
Sandoz International GmbH
UCB SA
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Axial Spondyloarthritis Overview 7
Therapeutics Development 8
Pipeline Products for Axial Spondyloarthritis - Overview 8
Axial Spondyloarthritis - Therapeutics under Development by Companies 9
Axial Spondyloarthritis - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Axial Spondyloarthritis - Products under Development by Companies 13
Axial Spondyloarthritis - Companies Involved in Therapeutics Development 14
Eli Lilly and Company 14
Johnson & Johnson 15
Novartis AG 16
Panacea Biotec Ltd 17
Sandoz International GmbH 18
UCB SA 19
Axial Spondyloarthritis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
adalimumab biosimilar - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
adalimumab biosimilar - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
adalimumab biosimilar - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
adalimumab biosimilar - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
certolizumab pegol - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Drug to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
etanercept biosimilar - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
ixekizumab - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
secukinumab - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
ustekinumab - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Axial Spondyloarthritis - Dormant Projects 75
Axial Spondyloarthritis - Product Development Milestones 76
Featured News & Press Releases 76
Nov 11, 2016: UCB Presents Data on Cimzia (certolizumab pegol) at 2016 ACR/ARHP Annual Meeting 76
Oct 25, 2016: Certolizumab pegol (Cimzia) AutoClicks Prefilled Pen - a New Self-injection Device Designed in Collaboration With Patients and Good Grips - is Now Available in the UK on the NHS 79
Jun 08, 2016: UCB commitment to addressing real world patient needs on display at the Annual European Congress of Rheumatology (EULAR 2016) 80
Nov 06, 2015: UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting 83
Nov 14, 2014: UCB Shows Strong Scientific Presence On Certolizumab pegol (CIMZIA) At Leading Rheumatology Meeting 88
Sep 20, 2013: UCB receives CHMP positive opinion for Cimzia in severe active axial spondyloarthritis 91
Jul 24, 2013: U.S. FDA Arthritis Advisory Committee Votes On Cimzia For Treatment of Adults with Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis 92
Jun 14, 2013: UCB's Certolizumab Pegol Rapidly Improves Pain, Fatigue And Physical Function In axSpA Patients In Phase III Study 93
Feb 20, 2013: UCB Announces Regulatory Filings For Cimzia To Treat Psoriatic Arthritis And Axial Spondyloarthritis 95
Nov 13, 2012: UCB Announces Presentation Of Phase III Trial Results Of Certolizumab Pegol In Axial Spondyloarthritis At ACR 2012 Annual Meeting 96
Nov 09, 2012: UCB To Present New Data On Certolizumab Pegol At ACR's 2012 Annual Scientific Meeting 98
Apr 16, 2012: UCB Announces Positive Top-Line Phase III Results Of Cimzia In Axial Spondyloarthritis And Ankylosing Spondylitis 100
Appendix 102
Methodology 102
Coverage 102
Secondary Research 102
Primary Research 102
Expert Panel Validation 102
Contact Us 102
Disclaimer 103
List of Tables
Number of Products under Development for Axial Spondyloarthritis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Comparative Analysis by Unknown Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Axial Spondyloarthritis - Pipeline by Eli Lilly and Company, H2 2016 14
Axial Spondyloarthritis - Pipeline by Johnson & Johnson, H2 2016 15
Axial Spondyloarthritis - Pipeline by Novartis AG, H2 2016 16
Axial Spondyloarthritis - Pipeline by Panacea Biotec Ltd, H2 2016 17
Axial Spondyloarthritis - Pipeline by Sandoz International GmbH, H2 2016 18
Axial Spondyloarthritis - Pipeline by UCB SA, H2 2016 19
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Stage and Target, H2 2016 22
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 28
Axial Spondyloarthritis - Dormant Projects, H2 2016 75
List of Figures
Number of Products under Development for Axial Spondyloarthritis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Targets, H2 2016 21
Number of Products by Stage and Targets, H2 2016 21
Number of Products by Mechanism of Actions, H2 2016 23
Number of Products by Stage and Mechanism of Actions, H2 2016 23
Number of Products by Routes of Administration, H2 2016 25
Number of Products by Stage and Routes of Administration, H2 2016 25
Number of Products by Molecule Types, H2 2016 27
Number of Products by Stage and Molecule Types, H2 2016 27
